Coronary Heart Disease
Conditions
Brief summary
The purpose of this study is to evaluate serial changes of neointimal coverage after everolimus-eluting stent implantation at 3-, 6- and 12-months by OCT examination.
Detailed description
Late and very late stent thrombosis is current main issue after introduction of drug-eluting stents .Possible causes of these stent thromboses include thrombus formation resulting from delayed neointimal coverage, spasms occurring at the distal end of the stent implantation site, positive remodeling of coronary arteries caused by local immune reaction to paclitaxel or rapamycin, and vascular endothelial damage induced by the polymer. For BMS, neointimal coverage begins within the first one month after stent implantation and almost completes in three months. For DES, sirolimus eluting stents (SES) for example, neointimal coverage is markedly delayed after stent implantation and the exposed stent struts may be largely attributable to the occurrence of late stent thrombosis. On the other hand, everolimus eluting stents (EES), which have a thinner stent strut layer and improved polymer biocompatibility, it has been reported that earlier and more normal neointimal coverage can be achieved compared with other first-generation DESs, SES and paclitaxel eluting stents (PES). These findings suggest that coverage with vascular endothelium differs among different DES platforms. Optical coherence tomography (OCT) has a resolution of 15 to 20 μm, which is approximately 10 times higher than that of intravascular ultrasound (IVUS). It is therefore necessary to use OCT to accurately evaluate cross-sectional images of the stent struts covered with vascular endothelium. However, no studies have reported the results of continuous observation and evaluation of EES covered with endothelium. Therefore, the investigators investigate time course of neointimal coverage of EES through detailed evaluation by OCT of neointimal coverage at 3, 6, and 12 months after stent implantation.
Interventions
None listed
Sponsors
Kobe University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Older than 20 years old. 2. Indication of PCI. 3. To agree to review and record all the clinical course in this research protocol. 4. The patient who are eligible to receive dual antiplatelet therapy at least more than 6 month. 5. Informed concent with the document signed by the patients. The patient have to correspond to all the above items at the time of registration.
Exclusion criteria
1. The patient who died during the research 2. The patient with Stent thrombosis during the research. 3. Previous history of pancytopenia, liver function, renal dysfunction, hypersensitive history of the drug. 4. Low ejection fraction (LVEF\<=30%), an impaired liver function, and renal dysfunction (eGFR\<=30) 5. The patient excluded from a safety of a thiazolidine derivative. lesion
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The percentage of neointimal coverage | 12 months | The primary endpoint is to evaluate the neointimal coverage of XIENCE everolimus eluting stent (EES) in 12 month after stent implantation by Optical coherence tomography |
Secondary
| Measure | Time frame |
|---|---|
| The percentage of neointimal coverage | 3 months |
Countries
Japan
Outcome results
None listed